Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept and dose-finding study of XXB750 in heart failure
jRCT2031230649Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Randomised, double-blind trial of xxb750 in heart failure (HF) (5 arms), sponsored by Novartis. Primary endpoint: Change in log NT-proBNP from baseline. Started Mar 2024; status: completed.
02
Drugs
xxb750
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT2031230649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230649.